ProteoGenix, Inc.: Series B $20M

ProteoGenix (Portland, OR) a diagnostics company utilizing high-throughput protein analysis techniques to identify protein biomarkers for pregnancy-related complications closed a $20M Series B round. The financing was led by New Leaf Venture Partners, TPG Growth and Burrill and Company.

Spaltudaq Corporation: Series B $29M

Spaltudaq (Seattle, WA) is focused on developing tumor-specific therapeutic antibodies for the treatment of cancer and infectious disease raised $29M in a Series B financing. The round was led by Arch Venture Partners and was joined by Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital and Alexandria Equities.

VentiRx Pharma, Inc.: Series A $26.6M

VentiRx Pharmaceuticals (Seattle, WA) a biopharmaceutical company focused on the development of medicines for the treatment of cancer and infectious, respiratory and autoimmune diseases, raised a $26.6M Series A round. The deal was led by Frazier Healthcare Ventures, ARCH Venture Partners and Domain Associates.

Calistoga Pharma, Inc.: Series A $21M

Calistoga Pharmaceuticals (Seattle, WA) a drug development startup focused on oncology and inflammation raised a $21M Series A. The deal was led by Frazier Healthcare Ventures and was joined by Alta Partners, Three Arch Partners and Amgen Ventures.

Chimerix, Inc.: Series D $23.1M

Chimerix (Seattle, WA) is applying its technology to the treatment of smallpox, cytomegalovirus infection, drug-resistant HIV infection, viral hepatitis, and macular degeneration, has closed $23.1M in Series D funding. Canaan Partners led the deal, and was joined by Alta Partners and return backers Sanderling Ventures, Asset Management Company and Frazier Healthcare Ventures.

Calistoga Pharma, Inc.: Series A $21M

Calistoga (Seattle, WA) a spinout of Icos, is developing compounds targeting p110 delta for cancer, inflammatory and autoimmune indications raised $21M in a series A round. The financing was led by Frazier Healthcare Ventures and Alta Partners and joined by Three Arch Partners and Amgen Ventures.

Omeros, Inc.: Series E $63M

Omeros (Seattle, WA) a biopharmaceutical company focused on improving joint function following arthroscopic surgeries raised $63M in a Series E financing. Investors included Aravis Ventures, Arch Venture Partners, American Financial Group, Grosvenor Funds, Novartis Venture Fund, Southern Cross Capital, Stanley Medical Research Institute, and Trevi Health Ventures.

Blue Heron Biotechnology, Inc.: Series D $3.7M

Blue Heron Biotechnology (Bothell, WA) a provider of gene synthesis services raised approximately $3.7M in Series D funding. Participants include Crabtree Ventures, Integra Ventures and Invitrogen.

EyeGate Pharma, Inc.: Series B $12M

EyeGate Pharma (Waltham, MA) a pharmaceutical company pioneering the use of iontophoresis technology to deliver therapeutics for ocular indications, announced that it has closed on a $2M extension of its Series B, bringing the total of the financing to $12M. This funding comes from the Nexus Group, the round was originally led by Innoven Partenaires and Ventech.